MET FISH-positive status predicts short progression-free survival and overall survival after gefitinib treatment in lung adenocarcinoma with EGFR mutation

Table 3 Univariate Cox proportional hazards models of factors associated with death and progression for all cases

Hazard ratios for death in according to prognostic factors
Characteristics	Comparison	Hazard ratio [95% CI ^a ]		*P value* ^b
Age	<65 yr vs. ≥65 yr	1.26	[0.50-3.17]	0.62
Gender	Female vs. Male	0.59	[0.23-1.49]	0.27
Smoking status	Never smoker vs. Ever smoker	0.41	[0.15-1.13]	0.08
Stage	III vs. IV/Relapse	1.46	[ 0.34-6.37]	0.61
*EGFR mutation type*	Exon19 deletion vs. Exon 21 L858R	1.90	[0.72-5.00]	0.62
MET FISH	Negative vs. Positive	2.25	[1.07-4.74]	0.03
Hazard ratios for progression in according to prognostic factors
Characteristics	Comparison	Hazard ratio [95% CI ^a ]		*P value* ^b
Age	<65 yr vs. ≥65 yr	0.52	[0.23-1.15]	0.11
Gender	Female vs. Male	0.88	[0.40-1.93]	0.75
Smoking stutus	Never smoker vs. Ever smoker	1.11	[0.51-2.42]	0.79
Stage	III vs. IV/Relapse	1.04	[0.30-3.64]	0.95
*EGFR mutation type*	Exon19 deletion vs. Exon 21 L858R	1.15	[0.45-2.91]	0.77
MET FISH	Negative vs. Positive	3.83	[1.75-8.38]	0.0008

ISSN: 1471-2407